隆盛科技(300680.SZ):談淵智不再是持股5%以上的股東
格隆匯 10 月 19日丨隆盛科技(300680.SZ)公佈,上市公司通過發行股份及支付現金的方式,購買談淵智、秦春森、王泳、姚邦豪、無錫凱利投資有限公司持有的無錫微研精密衝壓件有限公司100%股權。上述發行的股份已於2018年8月21日上市,信息披露義務人談淵智持有公司股份388.5723萬股,佔公司當時總股本的5.23%。由於公司進行年度分紅及轉增、向特定對象發行股票等原因,致使信息披露義務人持有公司的股份數量及比例發生變動。
此次權益變動後,信息披露義務人不再是持有公司5%以上股份的股東。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.